Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.38 |
| ▸ | PARP1 | P09874 | 2/20 | 0.37 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29531248 | 0.88 | PDE4B (0.43) | KMT2ANPC1RAB9ADPP4DPP7 | |
| SCHEMBL24159210 | 0.88 | PDE4B (0.43) | KMT2ANPC1RAB9ADPP4DPP7 | |
| SCHEMBL28107006 | 0.82 | NPC1 (0.42) | KMT2ANPC1RAB9ADPP4DPP7 | |
| SCHEMBL24159304 | 0.81 | KMT2A (0.38) | KMT2ANPC1RAB9ADPP4DPP7 | |
| SCHEMBL6043112 | 0.80 | CYP1A2 (0.44) | KMT2ANPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL1935423 | 0.80 | RAB9A (0.41) | KMT2ANPC1RAB9ADPP4DPP7 | |
| SCHEMBL18210083 | 0.79 | GAA (0.41) | KMT2ANPC1RAB9ADPP4DPP7 | |
| SCHEMBL27549913 | 0.79 | CHRM2 (0.39) | KMT2AGAAPDE4BNOS3NOS2 | |
| SCHEMBL7357348 | 0.79 | GAA (0.38) | KMT2AGAAPDE4BALDH1A1SMN1; SMN2 | |
| SCHEMBL8160540 | 0.78 | GAA (0.35) | GAAPDE4BALDH1A1NOS3NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116283920-B | 2, 4-disubstituted pyridine compound and application thereof | 贵州医科大学 | 2024-04-16 | — | — | CN | claimed |
| CN-116283920-A | 2, 4-disubstituted pyridine compound and application thereof | 贵州医科大学 | 2023-06-23 | — | — | CN | claimed |
| CN-115335359-A | Ocular targeting compounds and their use in treating ocular diseases | 比奥菲蒂斯公司 | 2022-11-11 | — | — | CN | claimed |
| EP-2142516-B1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | SANOFI SA (FR) | 2012-12-26 | — | — | EP | claimed |
| US-8258130-B2 | Pyrimidine hydrazide compounds as PGDS inhibitors | SANOFI (FR) | 2012-09-04 | — | — | US | claimed |
| US-20100048568-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | SANOFI-AVENTIS (FR) | 2010-02-25 | — | — | US | claimed |
| EP-2142516-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | Sanofi-Aventis (FR) | 2010-01-13 | — | — | EP | claimed |
| WO-2008121670-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | SANOFI-AVENTIS (FR) | 2008-10-09 | — | — | WO | claimed |
| US-20070117857-A1 | Substituted 3-amido-tetrahydro-indazolyl cannabinoid modulators | JANSSEN PHARMACEUTICA, N.V. | 2007-05-24 | — | — | US | claimed |
| CN-116178345-B | Substituted pyrimidinyl-pyridinyl-pyridone compound, and preparation method and application thereof | 深圳信立泰药业股份有限公司 | 2024-08-13 | — | — | CN | disclosed |
| CN-116283920-B | 2, 4-disubstituted pyridine compound and application thereof | 贵州医科大学 | 2024-04-16 | — | — | CN | disclosed |
| EP-4081507-B1 | CHEMICAL COMPOUNDS TARGETING THE EYE AND USE THEREOF IN THE TREATMENT OF EYE DISEASES | BIOPHYTIS (FR) | 2023-11-22 | — | — | EP | disclosed |
| CN-116283920-A | 2, 4-disubstituted pyridine compound and application thereof | 贵州医科大学 | 2023-06-23 | — | — | CN | disclosed |
| CN-116178345-A | Substituted pyrimidinyl-pyridinyl-pyridone compound, and preparation method and application thereof | 深圳信立泰药业股份有限公司 | 2023-05-30 | — | — | CN | disclosed |
| US-20100048568-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | SANOFI-AVENTIS (FR) | 2010-02-25 | — | — | US | disclosed |
| EP-2142516-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | Sanofi-Aventis (FR) | 2010-01-13 | — | — | EP | disclosed |
| WO-2008121670-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | SANOFI-AVENTIS (FR) | 2008-10-09 | — | — | WO | disclosed |
| EP-1931336-A1 | TETRAHYDRO-INDAZOLYL CANNABINOID MODULATORS | Janssen Pharmaceutica, N.V. (BE) | 2008-06-18 | — | — | EP | disclosed |
| US-20070117857-A1 | Substituted 3-amido-tetrahydro-indazolyl cannabinoid modulators | JANSSEN PHARMACEUTICA, N.V. | 2007-05-24 | — | — | US | disclosed |
| WO-2007038045-A1 | TETRAHYDRO-INDAZOLYL CANNABINOID MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117857-A1 | Substituted 3-amido-tetrahydro-indazolyl cannabinoid modulators | CNR2, CNR1, GPR18 | KMT2A 2775/4885NPC1 254/4885RAB9A 1003/4885 |
| US-20100048568-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | HRH2, HRH1, HRH4 | KMT2A 3378/4885NPC1 1657/4885RAB9A 2033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.